Español (ES)
English (UK)
Sylentis
About Sylentis
Mission & Vision
Awarded Management
Corporate Values
Our expertise
Contact
Technology
Understanding RNAi.
Video
Mechanism of action
Scientific Bibliography
ARVO 2017 Posters
Projects & Collaboration
Individual Projects
Collaborative Projects
Finalized Projects
Therapeutic Areas
Dry Eye Syndrome
Glaucoma
Ocular Allergies
Other research areas
R&D Products
R&D Pipeline
Tivanisiran (SYL1001)
Bamosirán
People & careers
What do we search?
What do we offer?
Join us
News
General news
Professional news
Sylentis
News
News
General news
Professional news
Sylentis-RSS
Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease
31/01/2019
Sylentis, PharmaMar Group, announces the end of patient recruitment for its HELIX trial
19/10/2018
The World Health Organization selects tivanisiran as the International Nonproprietary Name for SYL1001
19/10/2017
Sylentis sponsors the 11th OTS's Annual Meeting.
16/09/2015
Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics
17/11/2011
Sylentis, a pioneer in RNAi technology, obtains authorisation as research drug manufacturing laboratory
31/01/2011
Display #
5
10
15
20
25
30
50
100
All
JavaScript is currently disabled.
Please enable it for a better experience of
Jumi
.
